Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Eli Lilly stock rose after the drugmaker posted quarterly earnings that beat Wall Street expectations, and issued upbeat 2025 guidance. Fourth-quarter adjusted earnings came in at $5.32 a share, above ...

Eli Lilly earnings topped Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Stock futures are little changed as investors aim for a third-straight winning session. Google is the latest tech giant to ...

Tesla sales careened lower in Germany in January, as sales of the electric vehicle company headed by Elon Musk tumble across Europe. The TV spot marks the artificial-intelligence company's biggest ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

We disagree as this is an AI Arms Race and Alphabet is making the right moves at the right time. While this quarter was not a ...

Alphabet revenue misses expectations, Robinhood Markets says Super Bowl bets are off, and more news to start your day.

Good afternoon, and welcome to the WEC Energy Group's Conference Call for Fourth Quarter and Year-End 2024 Results. This call is being recorded for rebroadcast and all participants are in a ...

Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...